25 May 2022 15:00 until 25 August 2022 17:00

PVRI2021 Digital: Complete webinar series

AdobeStock_287763087 [Converted].jpg

PVRI2021 is an all-digital, monthly programme of cutting edge science

In light of the global health and safety recommendations, we will deliver our Annual World Congress in a digital format, in lieu of an in-person event, that was due to take place in January 2021. An ambitious programme entitled 'PVRI2021' has been put together by the Scientific Organising Committee and will feature monthly live sessions of the highest quality scientific content.


World Pulmonary Hypertension Day: Inaugural IDDI Webinar

The PVRI are delighted to announce that Dr. Martine Rothblatt has agreed to deliver a keynote presentation as part of an inaugural IDDI webinar on World Pulmonary Hypertension Day. The digital event will take place on 5 May 2021 at 15:00BST.

A message from our leadership

We are pleased to announce a series of digital sessions that continue the fantastic work of the PVRI for our global members and young scientists. In the absence of in-person meetings and symposia, this series will enable us to stay in contact with our worldwide community, but also allow us to continue to explore and discuss important new research.

During the live sessions, there will be ample time set aside for Q&A to encourage active participation from our audience. All presentations will be available to download after the event.

  • Registration to the each of the monthly sessions will be free for all PVRI members. You can log in here to check the status of your PVRI membership.

Abstract submissions

The PVRI is delighted to announce that we are now accepting abstract submissions for our digital programme, PVRI2021.

  • Abstract submission should be emailed, as a Word document (or pdf), Arial font 11, with no more than 300 words (abstract title, authors and institutions are not to be considered in calculating the wordage), to: Admin@pvrinstitute.org.
  • A 3 minute (maximum), 3 slide (maximum) presentation should accompany your submission, describing your work. This should be recorded using Microsoft Powerpoint's presentation recording tool. Details for this can be found here.
  • The 3-minute presentation will be featured on the PVRI website and promoted in our secure discussion forum and abstract programme. The main purpose of this presentation is to act as a supporting commentary that encourages discussion within the PVRI community. The presentation will be displayed throughout the year and can be updated as the author pleases. The intention of this new feature is to replace the in-person, moderated ‘walk-around’ at our live events.
  • All correspondence relating to abstracts will be undertaken by email with the first named author / registered presenter, so it is their responsibility to communicate any relevant information regarding the submitted abstract and the congress to the other authors.
  • The accuracy of the submitted abstract is the responsibility of the authors, so authors should prepare and proofread their abstracts carefully before submitting to ensure it is the final version.
  • All accepted abstracts will be published in our journal, Pulmonary Circulation.
  • There is no fee for abstract submission but you must have an active PVRI membership.

Scientific Organising Committee

Scientific leaders

  • Patricia Thistlethwaite, University of California, San Diego, USA (basic) 
  • Stephan Rosenkranz, University of Cologne, Germany (clinical) 

Scientific committee members

  • Sebastien Bonnet, Laval University, Canada 
  • Allan Lawrie, University of Sheffield, UK
  • Stelios Orfanos, University of Athens Medical School, Greece
  • Rogerio Souza, University of São Paulo, Brazil
  • Rebecca Vanderpool, University of Arizona College of Medicine – Tucson, USA

Senior advisor

  • Werner Seeger, PVRI President 2020/21, Justus-Liebig-University Giessen, Germany

Scientific programme

Webinar 1 // 27 January 2021

Around the globe: Global burden of pulmonary hypertension


  • The view of the World Heart Federation (WHF)
  • Role of WHO/NCDA in promoting global health with a focus on cardiovascular disease
  • Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME)
  • PVRI GoDeep: Perspectives of a global meta-registry
  • Best abstract
  • Best abstract

Webinar 2 // 24 February 2021

Keynote lecture session 2021


  • Keynote lecture 1: mHealth and wearables: Is this the dawn of a new age for cardiovascular medicine?
  • Keynote lecture 2: Sheila Glennis Haworth Memorial Lecture 
  • Best abstract
  • Best abstract
  • Best abstract

Webinar 3 // 24 March 2021

Connection between CoViD-19 and pulmonary vascular disease


  • SARS-1, MERS, SARS-2 and more: Are coronavirus infections an ubiquitous part of our lives?
  • Endothelitis and aberrant angiogenesis: Mechanisms of COVID-19 induced vascular injury
  • Venous thromboembolism in COVID-19: Prevalence and clinical picture
  • ACE-II receptors: Modulation of PVD in COVID-19?
  • Best abstract
  • Best abstract

Webinar 4 // 28 April 2021

Virtual poster discussion session 1


  • Round 1: Basic – 6 posters
  • Round 2: Clinical – 6 posters 

World Pulmonary Hypertension Day: Inaugural IDDI Webinar // 5 May 2021


  • Keynote presentation by Dr Martine Rothblatt

Webinar 5 // 26 May 2021

Novel imaging approaches in pulmonary hypertension patients


  • Update from the Fleischner Society Task Force for imaging in pulmonary hypertension
  • Molecular imaging of pulmonary vascular disease using microvascular endothelial cell ligands
  • MRI to assess pulmonary vascular changes and PH progression
  • Xenon magnetic resonance imaging signatures of PH
  • Synchrotron-based phase contrast micro-CT imaging of pulmonary vascular disease in human tissue and animal models

Webinar 6 // 23 June 2021

Joint Symposium with the ESC: The pulmonary circulation in the heart failure syndrome


  • The right ventricle in HFpEF
  • Genetic aspects in Group2 PH
  • Exercise haemodynamics in heart failure: What can we learn from invasive CPET?
  • Systemic consequences and interorgan cross-talk in heart failure and PH
  • Best abstract
  • Best abstract

Webinar 7 // 28 July 2021

Pro-Con debate session 1


Topic A: Role of pulmonary vascular pruning in PAH

  • PRO: A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH
  • CON: Remnants of lost pulmonary vasculature may be re-engaged in PAH

Topic B: Treatment of patients with mild PAH

  • PRO: Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs
  • CON: Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs

Webinar 8 // 25 August 2021

The notch receptors: Multi-regulators of PAH development


  • Role of notch1 in experimental pulmonary hypertension
  • Notch-BMPR interactions in endothelium in PAH
  • Notch3 is a driver and biomarker for PAH
  • Notch3 lineage and pulmonary vasculopathy

Webinar 9 // 29 September 2021

Beyond DNA: The unseen genome and novel omics approaches to PH


  • MicroRNAs and IncRNAs in right heart hypertrophy and failure
  • LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view
  • Epigenomics in pulmonary vascular remodelling
  • Integrative analysis of cell state changes with peripheral protein biomarkers
  • Novel omics approaches: clinical utility in PAH

Webinar 10 // 27 October 2021

Joint symposium with the ISHLT: End-stage PAH - how and what do we do in 2021?


  • When should a PH patient be considered for lung transplant?
  • Atrial septum defect creation or mechanical support for end-stage PAH
  • Lung and Heart-lung Transplant in 2021 – how well do PAH patients do?
  • Pluripotent stem cell-based approaches and the future of artificial lungs
  • Timing and extent of ventricular reverse remodelling after lung transplant for PH

Webinar 11 // 24 November 2021

Machine learning and artificial intelligence approaches for PH: From screening to novel drug targets


  • Looking beyond the hype: Applied AI and machine learning in translational medicine
  • Computational network pharmacology in cardiovascular disease:  Leveraging big data
  • Utilising artificial intelligence to screen and diagnose iPAH
  • Best abstract
  • Best abstract

Webinar 12 // 15 December 2021

Pro-Con debate session 2: Medical vs. surgical or interventional therapy for CTEPH


  • PRO: Riociguat should be given to all CTEPH patients, regardless of timing of PEA/BPA
  • CON: Riociguat should be given only to patients with inoperable or residual CTEPH after PEA/BPA
  • Best abstract
  • Best abstract
  • Best abstract
  • Best abstract
  • Best abstract

Webinar 13 // 26 January 2022

Virtual poster discussion session 2


  • Novel TRAF2 variant and KDR deletion are implicated in the pathogenesis of pulmonary arterial hypertension
  • Loss of Estrogen Receptor Alpha (ERα) Worsens Hemodynamic Alterations and Right Ventricular (RV) Adaptation in Female Rats with Pulmonary Hypertension (PH)
  • Breast cancer and heritable PAH due to BMPR2 mutation: an unexpected discovery
  • Smooth Muscle Tsc2 deficiency leads to spontaneous pulmonary hypertension and represents attractive molecular target for therapeutic intervention 
  • Identification of ADORA1-PDE10A Complex Formation and Its Bidirectional Regulation of Intracellular Cyclic AMP Levels as a Novel Therapeutic
  • Downregulation of adenylate kinase 4 (AK4) improves the mitochondrial respiration and inhibits the glycolytic switch of pulmonary arterial smooth muscle cells
  • Association between Leflunomide and Pulmonary Hypertension
  • The Estimand Framework in PAH Clinical Trials
  • Risk stratification in pulmonary hypertension due to chronic obstructive pulmonary disease
  • Small pulmonary vessels in severe pulmonary hypertension associated with chronic lung disease
  • A Phase 1, open-label, crossover study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects
  • Cardiac MRI and risk stratification in pulmonary arterial hypertension: evaluation of ESC/ERS thresholds for right atrial area

Webinar 14 // 23 February 2022

Bone marrow modulation of pulmonary vascular disease


  • Role of bone marrow in the pathogenesis of PAH
  • Role of bone marrow in the right ventricle remodelling
  • Reversal of PH by whole bone marrow transplantation in BMPR2 deficient mice
  • Bone marrow dependency of cigarette smoke-induced PH versus emphysema
  • Homologous bone marrow transplantation prevents the development of PAH in patients with severe scleroderma 

Webinar 15 // 30 March 2022

Aging and pulmonary hypertension: An endemic at the horizon?


  • Age-dependent prevalence of PH in the general population
  • Senescence mechanisms and pulmonary vascular aging
  • Metabolic syndrome and obesity leads to age-related PH
  • Genetics and epigenetics in age-related PH
  • Best abstract
  • Best abstract

Webinar 16 // 27 April 2022

The association between cancer and PH: A tale of two diseases


  • Cancer induced PH: Embolism as a major inducer
  • Cancer induced PH: Microenvironmental cancer niche as a major inducer
  • Cancer therapies induced PH
  • Cancer related signalling mechanisms underlying PH development
  • Best abstract
  • Best abstract

Webinar 17 // 25 May 2022

Professor Sheila Glennis Haworth Memorial Symposium on Paediatric PH


  • Genetics of pulmonary arterial hypertension: What we can learn by studying children with and without congenital heart disease
  • Therapeutic options in advanced PVD: Potts shunt versus lung transplantation
  • Stem cells and regenerative medicine for neonatal lung disease: Implications for COPD
  • Assessment of operability in patients with congenital heart disease and PAH: Fallacies and pitfalls
  • Best abstract
  • Best abstract

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI